CA
KZR

CHI Advisors’s Kezar Life Sciences KZR Stock Holding History

CHI Advisors’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-68,945
Closed -$2.16M – 27
2023
Q1 		$2.16M Sell
68,945
-120,000
-64% -$6.94M 0.57% 18
2022
Q4 		$13.3M Buy
188,945
+12,666
+7% +$939K 3.54% 8
2022
Q3 		$15.2M Sell
176,279
-7,800
-4% -$758K 4.08% 6
2022
Q2 		$15.2M Buy
184,079
+152,618
+485% +$13.5M 5.81% 6
2022
Q1 		$5.23M Buy
31,461
+4,236
+16% +$608K 2.22% 10
2021
Q4 		$4.55M Buy
27,225
+19,725
+263% +$2.23M 1.51% 14
2021
Q3 		$648K Sell
7,500
-7,168
-49% -$474K 0.19% 18
2021
Q2 		$796K Sell
14,668
-2,749
-16% -$156K 0.19% 18
2021
Q1 		$1.04M Buy
17,417
+3,917
+29% +$229K 0.21% 16
2020
Q4 		$705K Sell
13,500
-11,164
-45% -$621K 0.2% 16
2020
Q3 		$1.19M Sell
24,664
-9,433
-28% -$451K 0.42% 13
2020
Q2 		$1.77M Sell
34,097
-11,792
-26% -$595K 0.69% 9
2020
Q1 		$2M Buy
45,889
+30,463
+197% +$1.24M 4.72% 6
2019
Q4 		$619K Buy
15,426
+617
+4% +$19K 0.47% 12
2019
Q3 		$486K Buy
+14,809
New +$715K 0.47% 13

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CHI Advisors's KZR Position: Q2 2023 in Review

CHI Advisors sold out of Kezar Life Sciences (KZR) in Q2 2023, closing a stake of 68,945 shares — an estimated $2.16M sold.

CHI Advisors first reported a position in KZR in Q3 2019 and held it in 15 quarters. The position peaked at $15.2M in Q2 2022. 104 funds tracked by Wall St. Rank hold KZR as of Q2 2023.

  • CHI Advisors reported no remaining Kezar Life Sciences position as of Q2 2023 after selling out during the quarter.
  • CHI Advisors sold 68,945 Kezar Life Sciences shares in Q2 2023, an estimated $2.16M.
  • CHI Advisors first reported a position in Kezar Life Sciences in Q3 2019 and held it in 15 quarters.
  • CHI Advisors's Kezar Life Sciences position peaked at $15.2M in Q2 2022.
  • 104 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2023.

Based on CHI Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.